{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:20:34Z","timestamp":1794849634387,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00639-5","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:45:39Z","timestamp":1786689939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological effects of statins in systemic sclerosis: a systematic review and meta-analysis of 323 patients"],"prefix":"10.1007","volume":"34","author":[{"given":"Mostafa A.","family":"Khalifa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Hamzah M.","family":"Alghzawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehabeldin S.","family":"Anan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Al Rifai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayah A.","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder Ali Raheem","family":"Al-Saedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Awady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Elsayed","family":"Badr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obada","family":"Muayaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Bdarnh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fares","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Hegazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Jebril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"8","key":"639_CR1","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1002\/mco2.651","volume":"5","author":"X Wang","year":"2024","unstructured":"Wang X, He B. Endothelial dysfunction: molecular mechanisms and clinical implications. MedComm. 2024;5(8):e651.","journal-title":"MedComm"},{"key":"639_CR2","doi-asserted-by":"crossref","unstructured":"Khatiwada N, Hong Z. Potential benefits and risks associated with the use of statins. Pharmaceutics. 2024;16(2).","DOI":"10.3390\/pharmaceutics16020214"},{"issue":"5","key":"639_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17512433.2022.2072294","volume":"15","author":"A Zinellu","year":"2022","unstructured":"Zinellu A, Mangoni AA. A systematic review and meta-analysis of the effect of statin treatment on sVCAM-1 and sICAM-1. Expert Rev Clin Pharmacol. 2022;15(5):601\u201320.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"639_CR4","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1093\/rheumatology\/kead289","volume":"62","author":"L Ross","year":"2023","unstructured":"Ross L, Maltez N, Hughes M, Schoones JW, Baron M, Chung L, et al. Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. Rheumatology (Oxford). 2023;62(12):3785\u2013800.","journal-title":"Rheumatology (Oxford)"},{"key":"639_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.freeradbiomed.2025.12.033","volume":"245","author":"Y Hu","year":"2026","unstructured":"Hu Y, Ye X, Wu X, Mao R, Li Z, Han L, et al. Atorvastatin alleviates the progression of fibrosis in experimental systemic sclerosis: Binding to macrophage CD14 to regulate TLR4\/p65 or directly modulating fibroblast Smad3 signaling. Free Radic Biol Med. 2026;245:30\u201342.","journal-title":"Free Radic Biol Med"},{"key":"639_CR6","doi-asserted-by":"crossref","unstructured":"Zinellu A, Mangoni AA. Systematic review and meta-analysis of the effect of statins on circulating E-selectin, L-selectin, and P-selectin. Biomedicines. 2021;9(11).","DOI":"10.3390\/biomedicines9111707"},{"issue":"16","key":"639_CR7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1080\/14656566.2020.1793960","volume":"21","author":"ZH McMahan","year":"2020","unstructured":"McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother. 2020;21(16):2041\u201356.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"639_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s42358-024-00392-w","volume":"64","author":"C Kayser","year":"2024","unstructured":"Kayser C, de Oliveira Delgado SM, Zimmermann AF, Horimoto AMC, Del Rio APT, de Souza M\u00fcller C, et al. 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis. Adv Rheumatol. 2024;64(1):52.","journal-title":"Adv Rheumatol"},{"issue":"4","key":"639_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/sclerosis2040021","volume":"2","author":"K Bakopoulou","year":"2024","unstructured":"Bakopoulou K, Kaouri IE, Siliogka E, Siliogkas P, Shumnalieva R, Velikova T. Preclinical and clinical data on current therapeutic options for micro- and macrovascular abnormalities in systemic sclerosis. Sclerosis (London). 2024;2(4):322\u201340.","journal-title":"Sclerosis (London)"},{"key":"639_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2020;88:105906.","journal-title":"Int J Surg"},{"key":"639_CR11","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2024","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2024."},{"issue":"1","key":"639_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"639_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"1","key":"639_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/XEB.0000000000000155","volume":"17","author":"Z Jordan","year":"2019","unstructured":"Jordan Z, Lockwood C, Munn Z, Aromataris E. The updated Joanna Briggs Institute Model of Evidence-Based Healthcare. Int J Evid Based Healthc. 2019;17(1):58\u201371.","journal-title":"Int J Evid Based Healthc"},{"issue":"4","key":"639_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"issue":"5","key":"639_CR16","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1177\/0300060518762681","volume":"46","author":"PJ Kotyla","year":"2018","unstructured":"Kotyla PJ. Short course of simvastatin has no effect on markers of endothelial activation in normolipidemic patients with systemic sclerosis. J Int Med Res. 2018;46(5):1893\u2013901.","journal-title":"J Int Med Res"},{"issue":"6","key":"639_CR17","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/art.21899","volume":"54","author":"M Kuwana","year":"2006","unstructured":"Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 2006;54(6):1946\u201351.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"639_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s10165-009-0199-4","volume":"19","author":"M Kuwana","year":"2009","unstructured":"Kuwana M, Okazaki Y, Kaburaki J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol. 2009;19(5):530\u20135.","journal-title":"Mod Rheumatol"},{"key":"639_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1196\/annals.1423.070","volume":"1110","author":"A Abou-Raya","year":"2007","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M. Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Sci. 2007;1110:670\u201380.","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"639_CR20","first-page":"1801","volume":"35","author":"A Abou-Raya","year":"2008","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers. J Rheumatol. 2008;35(9):1801\u20138.","journal-title":"J Rheumatol"},{"key":"639_CR21","unstructured":"Del Papa N, Cortiana M, Vitali C, Silvestris I, Maglione W, Comina DP et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. - Abstract - Europe PMC [Internet]. 2008 [cited 2026 Feb 23]. Available from: https:\/\/europepmc.org\/article\/MED\/18528965"},{"issue":"5","key":"639_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/rheumatology\/keq003","volume":"49","author":"HY Sadik","year":"2010","unstructured":"Sadik HY, Moore TL, Vail A, Murray A, Anderson M, Blann A, et al. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology (Oxford). 2010;49(5):990\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"639_CR23","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1007\/s00296-011-2183-5","volume":"32","author":"M Rossi","year":"2012","unstructured":"Rossi M, Bazzichi L, Ghiadoni L, Mencaroni I, Franzoni F, Bombardieri S. Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients. Rheumatol Int. 2012;32(12):3715\u201321.","journal-title":"Rheumatol Int"},{"issue":"8","key":"639_CR24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/ard.2005.046870","volume":"65","author":"S Furukawa","year":"2006","unstructured":"Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis. 2006;65(8):1118\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"639_CR25","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1186\/ar4285","volume":"15","author":"O Tim\u00e1r","year":"2013","unstructured":"Tim\u00e1r O, Szekanecz Z, Kerekes G, V\u00e9gh J, Ol\u00e1h AV, Nagy G, et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis\u2013a prospective case-series study. Arthritis Res Ther. 2013;15(5):R105.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"639_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2025.100683","volume":"6","author":"W Xu","year":"2025","unstructured":"Xu W, Yau YK, Pan Y, Tse ETY, Lam CLK, Wan EYF. Effectiveness and safety of using statin therapy for the primary prevention of cardiovascular diseases in older patients with chronic kidney disease who are hypercholesterolemic: a target trial emulation study. Lancet Healthy Longev. 2025;6(3):100683.","journal-title":"Lancet Healthy Longev"},{"key":"639_CR27","doi-asserted-by":"publisher","first-page":"100887","DOI":"10.1016\/j.lanepe.2024.100887","volume":"40","author":"B Mihaylova","year":"2024","unstructured":"Mihaylova B, Wu R, Zhou J, Williams C, Schlackow I, Emberson J, et al. Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study. Lancet Reg Health Eur. 2024;40:100887.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"639_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11883-025-01386-9","volume":"28","author":"A Mahmoudi","year":"2026","unstructured":"Mahmoudi A, Katsiki N, Vrablik M, Sahebkar A. Pleiotropic effects of statins: focus on inflammation, oxidative stress and immunomodulation (part I). Curr Atheroscler Rep. 2026;28(1):8.","journal-title":"Curr Atheroscler Rep"},{"key":"639_CR29","doi-asserted-by":"crossref","unstructured":"Khan S, Huda B, Bhurka F, Patnaik R, Banerjee Y. Molecular and immunomodulatory mechanisms of statins in inflammation and cancer therapeutics with emphasis on the nf-\u03bab, nlrp3 inflammasome, and cytokine regulatory axes. Int J Mol Sci. 2025;26(17).","DOI":"10.3390\/ijms26178429"},{"issue":"5","key":"639_CR30","doi-asserted-by":"publisher","first-page":"e0323749","DOI":"10.1371\/journal.pone.0323749","volume":"20","author":"S Sabeel","year":"2025","unstructured":"Sabeel S, Motaung B, Nguyen KA, Ozturk M, Mukasa SL, Wolmarans K, et al. Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: A systematic review and meta-analysis. PLoS ONE. 2025;20(5):e0323749.","journal-title":"PLoS ONE"},{"issue":"8","key":"639_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.hlc.2023.04.300","volume":"32","author":"WB He","year":"2023","unstructured":"He WB, Ko HTK, Curtis AJ, Zoungas S, Woods RL, Tonkin A, et al. The effects of statins on cardiovascular and inflammatory biomarkers in primary prevention: a systematic review and meta-analysis. Heart Lung Circ. 2023;32(8):938\u201348.","journal-title":"Heart Lung Circ"},{"key":"639_CR32","unstructured":"Robyn Domsic M, Laffoon BG, Medsger T, Lafyatis R, Wisniewski S. The effect of atorvastatin on microvascular endothelial function and raynaud phenomenon in early diffuse scleroderma: Results of the Tamer\u2019 Study - ACR Meeting Abstracts [Internet]. [cited 2026 Feb 23]. Available from: https:\/\/acrabstracts.org\/abstract\/the-effect-of-atorvastatin-on-microvascular-endothelial-function-and-raynaud-phenomenon-in-early-diffuse-scleroderma-results-of-the-tamer-study\/"},{"key":"639_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.761721","volume":"8","author":"Z Gogulska","year":"2021","unstructured":"Gogulska Z, Smolenska Z, Turyn J, Mika A, Zdrojewski Z. Lipid alterations in systemic sclerosis. Front Mol Biosci. 2021;8:761721.","journal-title":"Front Mol Biosci"},{"issue":"9","key":"639_CR34","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00296-015-3241-1","volume":"35","author":"P Garc\u00eda de la Pe\u00f1a Lefebvre","year":"2015","unstructured":"Garc\u00eda de la Pe\u00f1a Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Rom\u00e1n Ivorra JA, et al. Efficacy of Raynaud\u2019s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int. 2015;35(9):1447\u201359.","journal-title":"Rheumatol Int"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00639-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00639-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:04:34Z","timestamp":1794848674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00639-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00639-5","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"58"}}